-Advertisement-
-Advertisement-
Geographic Atrophy
Avacincaptad pegol shows promising vision loss reduction in geographic atrophy
In a post hoc time-to-event analysis, there was a 59% risk reduction in the rate of vision loss in patients treated with avacincaptad pegol compared to sham at 12 months, according to a press release. The GATHER1 and GATHER2 clinical trials were designed to evaluate the rate of geographic atrophy...
Read More-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
Videos
22 Feb, 2023
Mark Dlugoss: Patients with geographic atrophy (GA), which is an...
Quizzes
-Advertisement-
-Advertisement-
Stay Connected! Join Our Newsletter
Contact
Grandin Library Building
Six Leigh Street
Clinton, New Jersey 08809
+908-505-8899
[email protected]
© 2023 Ophthalmology 360® is a trademark of International Healthcare Media, LLC. All rights Reserved